Your browser doesn't support javascript.
loading
Genome-wide CRISPR-Cas9 screen identified KLF11 as a druggable suppressor for sarcoma cancer stem cells.
Wang, Yicun; Wu, Jinhui; Chen, Hui; Yang, Yang; Xiao, Chengwu; Yi, Xiaoming; Shi, Changjie; Zhong, Ke; He, Haowei; Li, Yaoming; Wu, Zhenjie; Zhou, Guangxin; Rao, Qiu; Wang, Xiaoxia; Zhou, Xiaodie; Lomberk, Gwen; Liu, Bing; Zhao, Jianning; Ge, Jingping; Zhou, Wenquan; Chu, Xiaoyuan; Chen, Cheng; Zhou, Xuhui; Wang, Linhui; Guan, Kunliang; Qu, Le.
Afiliação
  • Wang Y; Department of Urology, Jinling Hospital, Clinical School of Medical College, Nanjing University, Nanjing 210002, China.
  • Wu J; Department of Orthopedic, Jinling Hospital, Clinical School of Medical College, Nanjing University, Nanjing 210002, China.
  • Chen H; Department of Orthopedic, Changzheng Hospital, Second Military Medical University, Shanghai 200003, China.
  • Yang Y; Department of Pathology, Jinling Hospital, Clinical School of Medical College, Nanjing University, Nanjing 210002, China.
  • Xiao C; Institute of Clinical Laboratory Medicine, Jinling Hospital, Clinical School of Medical College, Nanjing University, Nanjing 210002, China.
  • Yi X; Department of Urology, Changhai Hospital, Second Military Medical University, Shanghai 200433, China.
  • Shi C; Department of Urology, Jinling Hospital, Clinical School of Medical College, Nanjing University, Nanjing 210002, China.
  • Zhong K; Department of Urology, Jinling Hospital, Clinical School of Medical College, Nanjing University, Nanjing 210002, China.
  • He H; Department of Urology, Jinling Hospital, Clinical School of Medical College, Nanjing University, Nanjing 210002, China.
  • Li Y; Department of Urology, Jinling Hospital, Clinical School of Medical College, Nanjing University, Nanjing 210002, China.
  • Wu Z; Department of Urology, Daping Hospital, Third Military Medical University, Chongqing 400042, China.
  • Zhou G; Department of Urology, Changzheng Hospital, Second Military Medical University, Shanghai 200003, China.
  • Rao Q; Department of Orthopedic, Jinling Hospital, Clinical School of Medical College, Nanjing University, Nanjing 210002, China.
  • Wang X; Department of Pathology, Jinling Hospital, Clinical School of Medical College, Nanjing University, Nanjing 210002, China.
  • Zhou X; Department of Pathology, Jinling Hospital, Clinical School of Medical College, Nanjing University, Nanjing 210002, China.
  • Lomberk G; Department of Pathology, Jinling Hospital, Clinical School of Medical College, Nanjing University, Nanjing 210002, China.
  • Liu B; Department of Surgery, Medical College of Wisconsin Milwaukee, WI 53226, USA.
  • Zhao J; Department of Urology, Changzheng Hospital, Second Military Medical University, Shanghai 200003, China.
  • Ge J; Department of Orthopedic, Jinling Hospital, Clinical School of Medical College, Nanjing University, Nanjing 210002, China.
  • Zhou W; Department of Urology, Jinling Hospital, Clinical School of Medical College, Nanjing University, Nanjing 210002, China. septsoul@hotmail.com shzwqzsl@163.com gjp_doctor@qq.com chuxiaoyuan000@163.com chencheng1289@126.com zhouxuhui@smmu.edu.cn wanglinhui@smmu.edu.cn.
  • Chu X; Department of Urology, Jinling Hospital, Clinical School of Medical College, Nanjing University, Nanjing 210002, China. septsoul@hotmail.com shzwqzsl@163.com gjp_doctor@qq.com chuxiaoyuan000@163.com chencheng1289@126.com zhouxuhui@smmu.edu.cn wanglinhui@smmu.edu.cn.
  • Chen C; Department of Medical Oncology, Jinling Hospital, Clinical School of Medical College, Nanjing University, Nanjing 210002, China. septsoul@hotmail.com shzwqzsl@163.com gjp_doctor@qq.com chuxiaoyuan000@163.com chencheng1289@126.com zhouxuhui@smmu.edu.cn wanglinhui@smmu.edu.cn.
  • Zhou X; Department of Medical Oncology, Jinling Hospital, Clinical School of Medical College, Nanjing University, Nanjing 210002, China. septsoul@hotmail.com shzwqzsl@163.com gjp_doctor@qq.com chuxiaoyuan000@163.com chencheng1289@126.com zhouxuhui@smmu.edu.cn wanglinhui@smmu.edu.cn.
  • Wang L; Department of Orthopedic, Changzheng Hospital, Second Military Medical University, Shanghai 200003, China. septsoul@hotmail.com shzwqzsl@163.com gjp_doctor@qq.com chuxiaoyuan000@163.com chencheng1289@126.com zhouxuhui@smmu.edu.cn wanglinhui@smmu.edu.cn.
  • Guan K; Department of Urology, Changzheng Hospital, Second Military Medical University, Shanghai 200003, China. septsoul@hotmail.com shzwqzsl@163.com gjp_doctor@qq.com chuxiaoyuan000@163.com chencheng1289@126.com zhouxuhui@smmu.edu.cn wanglinhui@smmu.edu.cn.
  • Qu L; Department of Pharmacology and Moores Cancer Center, University of California San Diego, La Jolla, CA 92093, USA.
Sci Adv ; 7(5)2021 01.
Article em En | MEDLINE | ID: mdl-33571129
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Sarcoma / Sistemas CRISPR-Cas Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Sci Adv Ano de publicação: 2021 Tipo de documento: Article País de afiliação: China País de publicação: Estados Unidos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Sarcoma / Sistemas CRISPR-Cas Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Sci Adv Ano de publicação: 2021 Tipo de documento: Article País de afiliação: China País de publicação: Estados Unidos